Q-omics provides the consensus-scored RAC3 profile across patient tissues and cancer cell-line models. RAC3 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, RAC3 is differentially expressed in 14, with the highest sampling consensus in BLCA. Additionally, RAC3 RNA expression shows 19,821 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight KIRC, BLCA, and LSCC as cancer lineages where RAC3 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RAC3 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RAC3 survival associations across molecular data types. RAC3 RNA expression shows survival associations in the most cancer types (24), followed by mass-spec protein abundance (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RAC3 RNA expression–survival associations across cancer types. High RAC3 expression shows unfavorable associations in KIRC, ACC, BLCA, MESO, SKCM and UCEC. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for RAC3 RNA expression.
This table summarizes RAC3 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14, while mass-spec protein shows differences in 3. The strongest signals are observed in KIRC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for RAC3. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RAC3 shows lower tumor expression in KIRC and THCA and higher tumor expression in BLCA, LUAD, LUSC and COAD. The BLCA box plot shows higher RAC3 RNA expression in tumor versus normal tissue (log2 FC = +3.074, t-test p < 0.001).
This table shows molecular features associated with RAC3 in patient tissues and cancer cell lines. In patient samples, RAC3 shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, RAC3 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in OESOPHAGUS, while CRISPR and shRNA rows add functional-dependency signals in BONE and LUNG_SCLC.
